一是通過(guò)S-RBD特異性結(jié)合中和抗體的雙抗原夾心法，這種方法只采用S-RBD作為抗原來(lái)檢測(cè)總中和抗體，包括針對(duì)S-RBD中和表位的IgG、IgM、IgA總抗體，其靈敏度和特異性比單獨(dú)檢測(cè)IgG或IgM更高。
另一種是競(jìng)爭(zhēng)法策略，即利用基因工程技術(shù)表達(dá)的S-RBD蛋白和ACE2蛋白，模擬病毒與天然細(xì)胞上的受體結(jié)合，所檢測(cè)的如果是中和抗體就會(huì)抑制這兩種蛋白的結(jié)合。
近日據(jù)悉，北京熱景生物成功研發(fā)出新冠病毒中和抗體化學(xué)發(fā)光檢測(cè)試劑盒，該試劑基于競(jìng)爭(zhēng)法，既有單人份包裝規(guī)格，也有匹配高通量全自動(dòng)化學(xué)發(fā)光分析儀的規(guī)格，可以為疫苗接種免疫效果的評(píng)估提供快速檢測(cè)手段。此前，熱景生物已成功開(kāi)發(fā)出膠體金法、上轉(zhuǎn)發(fā)光法新冠病毒中和抗體檢測(cè)試劑，加上化學(xué)發(fā)光法中和抗體檢測(cè)試劑，形成了適用于不同應(yīng)用場(chǎng)景的新冠病毒免疫評(píng)估整體解決方案，目前這些試劑盒均已獲得歐盟CE認(rèn)證。
【參考文獻(xiàn)】
[1]Jee Young Chung, Melissa N. Thone, Young Jik Kwon. COVID-19 vaccines: The status and perspectives in delivery points of view. Advanced Drug Delivery Reviews, 170 (2021) 1–25.
[2]Wanbo Tai1 , Lei He,et al.Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.Cellular & Molecular Immunology (2020) 17:613 – 620.
[3]Markus Hoffmann,et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.Cell 181, 271–280.
[4]Sana O. Alturki,et al.Current SARS-CoV-2 Vaccine Development .Frontiers in Immunology,August 2020 ,Volume 11,Article 1880.
[5]Premkumar, L. et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol. 5, eabc8413 (2020).
[6]Wan, J. et al. Human-IgG-neutralizing monoclonal antibodies block the SARS-CoV-2 infection. Cell Rep. 32, 107918 (2020).
[7]Yuan, M., Liu, H., Wu, N. C. & Wilson, I. A. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Biochem. Biophys. Res. Commun. https://doi. org/10.1016/j.bbrc.2020.10.012 (2020).
[8]Sun, J. et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell 182, 734–743 (2020).
[9]Du, L., He, Y., Jiang, S. & Zheng, B. J. Development of subunit vaccines against severe acute respiratory syndrome. Drugs Today 44, 63–73 (2008).
聯(lián)系客服
